Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Correlation of 68Ga-PSMA PET/CT SUV and Gleason Score in Prostate Cancer
NCT02796807Phase 2Completed
- Sponsor
- Jewish General Hospital
- Start
- May 2016
- Primary completion
- Dec 2017
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by Jewish General Hospital. Started May 2016; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02796807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02796807.